Drug Development Portfolio
Drug
Partner
License
Feasibility
Preclinical
Clinical trials
Regulatory
Submissions Approved Sales
(royalties)
Submissions Approved Sales
(royalties)
iNKT cell platform (oncology)
CAR19-iNKT
Second CAR-iNKT target
New CAR-iNKT
Additional Indications
Anagrelide (solid tumors)
ZolpiMist (insomnia)*
Sumatriptan (migraine)
Medical Grade Cannabis
Undisclosed
*ZolpiMist has been approved by the TGA and the FDA. SUDA holds the licence to ZolpiMist outside of North America